Joshua Meeks

Urologic Oncologist and Scientist at Northwestern University
K-index:3.7

[NEJM @NEJM]

Presented at #ASCO26:

In high-risk localized prostate cancer, ADT plus apalutamide led to a pathological complete response or minimal residual disease and 5-year metastasis-free survival in a greater percentage of patients than ADT plus placebo. Full phase 3 PROTEUS trial results: https://t.co/UxXUkYwd8Z

Editorial: A Watershed Moment in the Perioperative Treatment of Prostate Cancer https://t.co/XgeWL3lqy6

@ASCO

[Uromigos @Uromigos]

We ran a mock ODAC for sasanlimab and durvalumab in high risk NMIBC. Results showed one of the agents received more support than the other. This felt surprising and is timely in vote of the recent FDA decisions. #ASCO26 👉 https://t.co/1Hnhfxr11A

[FDA Oncology @FDAOncology]

#FDA approves a treatment for high-risk non-muscle invasive bladder cancer. https://t.co/KHPP0Drkg0

[Joshua Meeks @JoshMeeks]

@OncBrothers @US_FDA @BijoyTelivala @apolo_andrea @TiansterZhang @PGrivasMDPhD @RenoHemonc @dr_yakupergun @siadaneshmand @shilpaonc @DrYukselUrun It’s a big tent

[Joshua Meeks @JoshMeeks]

@UroDocAsh Congratulations- incredibly well deserved.

[Joshua Meeks @JoshMeeks]

@FaltasLab @BladderCancerUS @BCAN_Research @WeillCornell @Cornell @WCMGUcancer @WCMDeptofMed @WCMEnglanderIPM Happy birthday and congrats on the success !!

[Joshua Meeks @JoshMeeks]

@VigneshPackiam We need @RutgersCancer to open and enroll! 🤞@SWOG

[Joshua Meeks @JoshMeeks]

@ChapinMD @UroCancer @UroOnc @UTMDAnderson @KKBree @nnavai @jdhdavis @DrByronLee @BCottaMD @OLWMD @UroDocAsh @JustinRGregg @lislycherymd @sgswisher @ppisters Congrats @KKBree !

[Joshua Meeks @JoshMeeks]

@IBCG_BladderCA TMT debate on radiation toxicity #AUA26

[Joshua Meeks @JoshMeeks]

GI-Coffee study. Coffee vs alvimopan for MIBC after cystectomy for bowel recovery. Great study. Worry about contamination of baseline coffee use across both arms.

[Joshua Meeks @JoshMeeks]

Please open and enroll to GAIN. @eugene_pietzak gem-bcg. Bcg exposed. Great trial. We have open and enrolling @NM_Urology

[Joshua Meeks @JoshMeeks]

@MaxKates NDV01. Gel- gem-doce Vs obs for IR. Hard to know if obs is the best control.

[Joshua Meeks @JoshMeeks]

MR3🌑 ErdaiDRS. BCG unresponsive. (It’s like SR5-> FGFR3)

[Joshua Meeks @JoshMeeks]

MR2🌑 FGFR3 agnostic. Ablative (noTURBT) for IR. results coming.

[Joshua Meeks @JoshMeeks]

TIP#5 Tyra-300 IR NMIBC. oral FGFR3

[Joshua Meeks @JoshMeeks]

TIP#3 Enlighted Ph3. VTP for UTUC. very reasonable response for LG UTUC

[Joshua Meeks @JoshMeeks]

TIP#2. So excited for ARCIS. @SWOG. First RCT of BCG unresponsive NMIBC. CRETO-gem vs gem-doce.
@MarkTysonMD @cgoncology

[Joshua Meeks @JoshMeeks]

TIP#1 Bel-sar. Novel neoajuvant injection mechanism. #AUA2026

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

Come join us for a deep dive into Clinical Trials in Progress - Hall B, The Square, Learning Lab ... at 9 am ET TODAY #AUA26